Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar in Safety and Effi

    1. Linnebjerg, H, Lam E, et al. Comparative Pharmacokinetics (PK) and
       Pharmacodynamics (PD) of LY2963016 Insulin Glargine and EU- and
       US-approved Versions of Lantus Insulin Glargine in Healthy Subjects.
       Abstract 889-P. Presented at 74(th) American Diabetes Association (ADA)
       Scientific Sessions; June 13-17, 2014; San Francisco, CA.
    2. Zhang, X, Lam, E, et al. Comparative Pharmacokinetics and
       Pharmacodynamics of Two Insulin Glargine Products, LY2963016 and
       Lantus, in Healthy Subjects at Two Dose Levels. Abstract 890-P.
       Presented at 74th American Diabetes Association (ADA) Scientific
       Sessions; June 13-17, 2014; San Francisco, CA.
    3. Heise, T, Zhang, X, et al. Duration of Action of 2 Insulin Glargine
       Products, LY2963016 and Lantus, in Subjects with Type 1 Diabetes
       Mellitus (T1DM). Abstract 891-P. Presented at 74th American Diabetes
       Association (ADA) Scientific Sessions; June 13-17, 2014; San Francisco,
       CA.
    4. Blevins, T, Dahl, D, et al. Similar Efficacy and Safety with LY2963016
       Insulin Glargine Compared with Lantus Insulin Glargine in Patients with
       T1D: the ELEMENT 1 Study. Abstract 69-OR. Presented at 74th American
       Diabetes Association (ADA) Scientific Sessions; June 13-17, 2014; San
       Francisco, CA.
    5. Rosenstock, J, Hollander, P, et al. Similar Efficacy and Safety with
       LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in
       Patients with T2D: the ELEMENT 2 Study. Abstract 64-OR. Presented at 74th
       American Diabetes Association (ADA) Scientific Sessions; June 13-17,
       2014; San Francisco, CA.
    6. Deeg, M, Ilag, L, et al. Evaluation of Immunogenicity of LY2963016
       Insulin Glargine Compared with Lantus Insulin Glargine in Patients with
       T1D or T2D. Abstract 70-OR. Presented at 74th American Diabetes
       Association (ADA) Scientific Sessions; June 13-17, 2014; San Francisco,
       CA.
    7. Inzucchi SE, Bergenstal RM, et al. Management of Hyperglycemia inType2
       Diabetes: A Patient-Centered Approach. Diabetes Care June 2012 vol. 35
       no. 6 1364-1379.
    8. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels,
       Belgium: International Diabetes Federation, 2013.
       http://www.idf.org/diabetesatlas [http://www.idf.org/diabetesatlas].